Optimising zoledronate treatment holiday duration without loss of fracture prevention
Osteoporosis is characterised by reduced bone mass and disordered bone microstructure, which collectively result in increased fracture risk. Data from the National Health and Nutrition Examination Survey document a prevalence of osteoporosis of 12·6% in adults aged 50 years or older in the USA, with a preponderance in women (18·8%) versus men (4·2%).1 Although reported absolute fracture rates vary somewhat by country, it is anticipated that fracture incidence will increase with ageing of the global population, with the annual number of hip fractures specifically expected to double between 2018 and 2050.